Lauder for supplementing monograph
This article was originally published in The Rose Sheet
Executive Summary
Sunscreen ingredients bemotrizinol and bisoctrizole should be added to FDA's OTC sunscreen monograph, Estee Lauder asserts in Nov. 1 comments to the agency, in support of time and extent applications filed by Ciba in April 2005. After reviewing the applications, FDA recommended initially that both ingredients (up to 10% each) be recommended for monograph inclusion. Then in a Dec. 5 Federal Register notice, the agency issued a call for data on bemotrizinol and bisoctrizole as single active ingredients and in combination with other active ingredients in sunscreen products (1"The Rose Sheet" Dec. 12, 2005, p. 3). "The Lauder Companies would like to offer our consumers more broad-spectrum, photostable UVA protective sunscreen products that will protect them from both UVA and UVB," Lauder states, adding: "We petition you to approve these sunscreen actives as soon as possible"...
You may also be interested in...
FDA Will Consider Triclosan For OTC Acne Monograph Inclusion
FDA is seeking data on use of triclosan in topical acne treatment products, the agency announced in a Dec. 5 Federal Register 1notice
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.